Brief: Resonance Health Contracted For Clinical Drug Trial Worth A$6.33 Million Over 18 Months
18/08/2023 02:19
Aug 18 (Reuters) - Resonance Health Ltd RHT.AX :
* CONTRACTED BY SUN PHARMACEUTICAL INDUSTRIES
* CONTRACTED FOR CLINICAL DRUG TRIAL WORTH A$6.33 MILLION
OVER 18
MONTHS
* RESONANCE WILL PROVIDE ITS IMAGING ANALYSIS SERVICES AT
VARIOUS
TIMEPOINTS THROUGHOUT CLINICAL TRIAL, AMONG OTHERS
Source text for Eikon: ID:nASX7TGbc2
Further company coverage: RHT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Resonance Health
See all newsAustralia's Resonance Health jumps on FY26 forecast hike
Brief: Resonance Health Expects FY26 Underlying EBITDA A$2.6 Mln
Brief: Resonance Health Says Martin Blake Retires As Chair
Brief: Resonance Health Contracted For Clinical Drug Trial Worth A$13.775 Mln
Brief: Resonance Seeks Trading Halt Pending Announcement On Execution Of Contract For Services For Clinical Trial By Pharma Co